公开(公告)号：US20150299129A1

公开(公告)日：2015-10-22

申请号：US14789149

申请日：2015-07-01

申请人： ABIVAX ,  CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE MONTPELLIER 2

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Jamal TAZI ,  Gilles GADEA ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D215/42 ,  C07D215/38 ,  C07D215/46

CPC分类号： C07D403/12 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D241/44 ,  C07D401/12

摘要： A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

摘要翻译： 一种预防，抑制或治疗癌症的方法，包括使细胞与至少一种式（Ia）化合物或其药学上可接受的盐接触：其中：R独立地表示氢原子，卤素原子，（C1-C3 ）烷基，-CN基，羟基，-COOR1基，（C1-C3）氟代烷基，-NO2基，-NR1R2基或（C1-C3）烷氧基; R'是氢原子，卤素原子，（C1-C3）烷基，-NO2基，（C1-C3）烷氧基或-NR1R2基团; 并且R 1和R 2是氢原子或（C 1 -C 3）烷基。

公开(公告)号：US20140080831A1

公开(公告)日：2014-03-20

申请号：US14087762

申请日：2013-11-22

申请人： CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE ,  UNIVERSITE MONTPELLIER 2 ,  SOCIETE SPLICOS ,  INSTITUT CURIE

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Jamal TAZI ,  Gilles GADEA ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/12 ,  C07D215/46 ,  C07D403/12 ,  C07D215/42 ,  C07D215/38 ,  C07D241/44

CPC分类号： C07D403/12 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D241/44 ,  C07D401/12

摘要： A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

摘要翻译： 一种预防，抑制或治疗癌症的方法，包括使细胞与至少一种式（Ia）化合物或其药学上可接受的盐接触：其中：R独立地表示氢原子，卤素原子，（C1-C3 ）烷基，-CN基，羟基，-COOR1基，（C1-C3）氟代烷基，-NO2基，-NR1R2基或（C1-C3）烷氧基; R'是氢原子，卤素原子，（C1-C3）烷基，-NO2基，（C1-C3）烷氧基或-NR1R2基团; 并且R 1和R 2是氢原子或（C 1 -C 3）烷基。

公开(公告)号：US20170226095A1

公开(公告)日：2017-08-10

申请号：US15486836

申请日：2017-04-13

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D217/02 ,  C07D401/12 ,  C07D403/12 ,  C07D215/38 ,  C07D241/44

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20220127253A1

公开(公告)日：2022-04-28

申请号：US17327079

申请日：2021-05-21

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12 ,  C07D217/02 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/42 ,  C07D215/46

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20200239444A1

公开(公告)日：2020-07-30

申请号：US16848916

申请日：2020-04-15

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Gilles GADEA ,  Jamal TAZI ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/14 ,  C07D239/42 ,  C07D401/12 ,  C07D213/75

摘要： A compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

公开(公告)号：US20240343716A1

公开(公告)日：2024-10-17

申请号：US18435619

申请日：2024-02-07

申请人： ABIVAX ,  CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:




where:



R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;
R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and
R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

公开(公告)号：US20180222888A1

公开(公告)日：2018-08-09

申请号：US15946120

申请日：2018-04-05

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Gilles GADEA ,  Jamal TAZI ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/14 ,  C07D239/42 ,  C07D213/75 ,  C07D401/12

摘要： The present invention relates to a compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

公开(公告)号：US20150315173A1

公开(公告)日：2015-11-05

申请号：US14432328

申请日：2013-09-30

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Pierre ROUX ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Gilles GADEA ,  Jamal TAZI ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC

IPC分类号： C07D401/14 ,  C07D239/42 ,  C07D401/12 ,  C07D213/75

CPC分类号： C07D401/14 ,  C07D213/75 ,  C07D239/42 ,  C07D401/12

摘要： The present invention relates to a compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

摘要翻译： 本发明涉及式（I）化合物：其中A和A'独立地表示亚苯基或亚吡啶基; R2是氢原子或（C1-C4）烷基; R3是2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基或5-嘧啶基; R4是羰基或磺酰基; 并且R 5为-NH-（CH 2）a -NR 6 R 7基或4-甲基哌嗪基，其为1至4的整数，R 6和R 7独立地表示（C 1 -C 4）烷基，或者R 6和R 7一起 与它们相连的氮原子形成选自4-甲基哌嗪基，吗啉基，吡咯烷基和哌啶子基的杂环基; 或其药学上可接受的盐中的任何一种。